profit from every $100 of sales.
$0$100
biote
$1.11+4.72% today
-59.0% in 1 year
1-year low $1.031-year high $2.85
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $1.39 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What biote sold, what it kept, and what it did with the cash.
Sales went from $165 million in 2022 to $192 million in 2025, with $27.0 million of profit last year.
SalesProfit
biote handed back 18% of the cash it generated last year.
Buybacks $3M$2M
Free cash flow 2025$28M
Bought back its own shares$3M
Paid as dividends$2M
Cash vs. debt$24M vs. $110M
biote vs. similar companies
biote grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| biote | 1.4× · Cheap | ||
 Tenet Healthcare | 16.3× · Fair price | ||
 Solventum | 9.9× · Cheap | ||
 Encompass Health | 24.5× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.8× · Cheap |
AI analysis
An AI analyst reads biote's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 165 | 185 | 197 | 192 | |
| 110 | 127 | 139 | 137 | |
| -61 | 29 | 32 | 36 | |
| 8 | 9 | 16 | 52 | |
| -1 | 3 | 3 | 27 | |
| -0.12 | 0.13 | 0.09 | 0.74 | |
| 66.9% | 68.8% | 70.5% | 71.5% | |
| -36.8% | 15.5% | 16.0% | 18.5% | |
| -0.6% | 1.8% | 1.6% | 14.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 112 | 155 | 122 | 108 |
| Cash | 79 | 89 | 39 | 24 |
| Total debt | 120 | 115 | 111 | 110 |
| Total liabilities | 170 | 192 | 225 | 158 |
| -44 | -29 | -106 | -59 | |
| 8 | 26 | 34 | 37 | |
| 6.0% | 5.8% | 192.4% | 74.6% | |
| 2.2% | -11.3% | -3.0% | -46.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9 | 27 | 45 | 35 | |
| 2 | 3 | 7 | 7 | |
| -11 | 24 | 38 | 28 | |
| Dividends paid | 13 | 9 | 5 | 2 |
| 0 | 0 | 6 | 3 | |
| 82 | 9 | 9 | 9 |
Valuation
- 1.4×
- 3.8×
- –
- -1.0×
- 0.2×
- 1.3×
- 2.4×
- 75.3%
- 71.9%
- 0.0%
Profitability
- 71.5%
- 18.5%
- 14.1%
- 19.0%
- 37.1%
- 39.6%
- -22.9%
- 17.5%
- 52.6%
- –
Growth
- +5.2%
- –
- −22.2%
- –
- +42.6%
Financial health
- 2.9×
- -1.93
- 121.8%
- 3.2×
- 1.29
- 0.58
- 2.11
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 2%of 948
Top 27%of 871
Top 1%of 560
Bottom 28%of 868
Top 1%of 985
What analysts expect
- Average price target
- $3.25
- Range
- $2.50 – $4.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.06 | 0.09 | −33.3% |
| Mar 11, 2026 | 0.06 | 0.05 | +20.0% |
| Nov 5, 2025 | 0.22 | 0.05 | +340.0% |
| Aug 6, 2025 | 0.10 | 0.06 | +66.7% |
| May 7, 2025 | 0.08 | 0.06 | +33.3% |
| Mar 12, 2025 | 0.10 | 0.09 | +11.1% |
| Nov 12, 2024 | 0.33 | 0.09 | +266.7% |
| Aug 8, 2024 | 0.14 | 0.09 | +55.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
66Pass
Benjamin Graham
62Pass
Philip Fisher
62Pass
Peter Lynch
47No pass
Joel Greenblatt
93Pass
Charlie Munger
74Pass
Terry Smith
78Pass
Questions about biote
Is biote a good stock to buy?
A solid business, and the price looks low. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the biote AI analysis
What does biote do?
biote Corp. operates in medical practice-building business within the hormone optimization space. It is in Medical - Care Facilities.
Does biote pay a dividend?
Yes. In 2025 it paid out $1.73 million in dividends.
Is biote stock halal?
No. biote does not pass our halal screen: its debt is 292% of its market value, at or above the 33% limit. How we check
How has biote stock done over the past year?
Down 59.0% over the past twelve months, to $1.11. It traded between $1.03 and $2.85 and is 61.1% below its high.
Who are biote's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with biote's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.